



# FACTBOOK

2023年12月期第2四半期  
Three months Ended June 30, 2023

株式会社ジーエヌアイグループ  
GNI Group Ltd.

*No Contents*

---

- 01 Consolidated Financial Highlights
- 02 Consolidated Statement of Income
- 03 Consolidated Statements of Financial Position
- 04 Consolidated Segment Information
- 05 Profitability-related Indicators
- 06 Operating Profit before R&D
- 07 Stock Information

**Consolidated Financial Highlights**

(Unit : Million yen)	FY2021				FY2022				FY2023		
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD	YTD Forecast
Revenue	3,872	6,465	9,536	<b>12,690</b>	3,933	8,154	12,761	<b>17,418</b>	4,206	<b>14,096</b>	25,273
Cost of Sales	455	785	1,209	<b>1,600</b>	549	1,134	1,907	<b>2,674</b>	573	<b>1,341</b>	-
Gross Profit	3,416	5,679	8,327	<b>11,089</b>	3,384	7,020	10,853	<b>14,744</b>	3,632	<b>12,755</b>	-
<i>Gross Profit Margin</i>	88.2%	87.8%	87.3%	<b>87.4%</b>	86.0%	86.1%	85.0%	<b>84.6%</b>	86.4%	<b>90.5%</b>	-
Selling, General and Administrative Expenses	2,194	3,677	5,503	<b>7,958</b>	2,458	4,765	7,498	<b>10,965</b>	2,646	<b>6,179</b>	-
Personnel Expenses	784	1,420	2,080	<b>2,983</b>	964	1,892	2,733	<b>3,636</b>	965	<b>1,964</b>	-
Research and Development Expenses	403	864	1,417	<b>2,015</b>	468	1,089	1,819	<b>2,545</b>	635	<b>1,253</b>	-
Operating Profit	773	1,455	1,960	<b>1,624</b>	478	1,004	1,494	<b>1,377</b>	397	<b>5,476</b>	5,991
<i>Operating Profit Margin</i>	20.0%	22.5%	20.6%	<b>12.8%</b>	12.2%	12.3%	11.7%	<b>7.9%</b>	9.4%	<b>38.8%</b>	23.7%
Profit before Tax	676	1,197	1,568	<b>1,107</b>	347	790	1,223	<b>767</b>	64	<b>5,117</b>	4,143
Profit before Tax Margin	17.5%	18.5%	16.4%	<b>8.7%</b>	8.8%	9.7%	9.6%	<b>4.4%</b>	1.5%	<b>36.3%</b>	-
Net Profit	435	744	874	<b>55</b>	72	197	324	<b>868</b>	341	<b>4,014</b>	2,174
<i>Net Profit Margin</i>	11.2%	11.5%	9.2%	<b>0.4%</b>	1.8%	2.4%	2.5%	<b>5.0%</b>	8.1%	<b>28.5%</b>	8.6%
Profit Attributable to Owners of Parent	432	941	1,294	<b>1,066</b>	351	676	1,076	<b>388</b>	2	<b>1,658</b>	1,703
Minority Interest	3	196	419	<b>1,010</b>	278	478	751	<b>1,257</b>	338	<b>2,355</b>	-
<i>Profit Attributable to Owners of Parent Margin</i>	11.2%	14.6%	13.6%	<b>8.4%</b>	8.9%	8.3%	8.4%	<b>2.2%</b>	0.0%	<b>11.8%</b>	6.7%
Total Assets	27,117	28,990	29,788	<b>30,296</b>	32,590	35,266	36,456	<b>33,906</b>	34,070	<b>45,050</b>	-
Net Assets	17,267	19,080	19,429	<b>19,266</b>	20,473	21,762	22,015	<b>19,810</b>	19,786	<b>24,798</b>	-
Equity Ratio	63.7%	65.8%	65.2%	<b>63.6%</b>	62.8%	61.7%	60.4%	<b>58.4%</b>	58.1%	<b>55.0%</b>	-
ROE	2.5%	3.9%	4.5%	<b>0.3%</b>	0.4%	0.9%	1.5%	<b>4.4%</b>	1.7%	<b>16.2%</b>	-
ROA	1.6%	2.6%	2.9%	<b>0.2%</b>	0.2%	0.6%	0.9%	<b>2.6%</b>	1.0%	<b>8.9%</b>	-
EPS	9.50	20.30	27.69	<b>22.72</b>	7.40	14.25	22.67	<b>8.19</b>	0.06	<b>34.93</b>	35.86
EPS (diluted basis)	9.12	19.73	26.87	<b>22.08</b>	7.36	14.18	22.46	<b>8.11</b>	0.06	<b>34.81</b>	-

FX rate used in forecast: 1 USD = 130.77 JPY / 1 RMB = 19.38 JPY

## Consolidated Statement of Income

(Unit : Million yen)	FY2022				FY2023	
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD
Revenue	3,933	8,154	12,761	17,418	4,206	14,096
Cost of Sales	549	1,134	1,907	2,674	573	1,341
Gross Profit	3,384	7,020	10,853	14,744	3,632	12,755
Selling, General and Administrative Expenses	2,458	4,765	7,498	10,965	2,646	6,179
Personnel Expenses	965	1,892	2,733	3,636	966	1,965
Research and Development Expenses	468	1,089	1,819	2,545	635	1,253
Operating Profit	478	1,004	1,494	1,377	397	5,476
Finance Income	54	175	347	259	49	306
Finance Costs	186	390	618	869	239	539
Share of Profit of Entities Accounted for Using Equity Method	0	0	0	0	0	146
Share of Loss of Entities Accounted for Using Equity Method	0	0	0	0	272	272
Profit before Tax	347	790	1,223	767	64	5,117
Profit Attributable to Owners of Parent	351	676	1,076	388	2	1,658

## **Consolidated Statements of Financial Position**

(Unit : Million yen)	FY2022				FY2023	
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD
<b>Assets</b>						
Non-current Assets	13,052	15,290	17,208	<b>16,759</b>	17,723	<b>20,232</b>
Current Assets	19,537	19,976	19,248	<b>17,147</b>	16,347	<b>24,818</b>
<b>Total Assets</b>	<b>32,590</b>	<b>35,266</b>	<b>36,456</b>	<b>33,906</b>	<b>34,070</b>	<b>45,050</b>
<b>Liabilities</b>						
Non-current Liabilities	9,159	10,554	11,593	<b>10,592</b>	10,835	<b>15,694</b>
Current Liabilities	2,957	2,949	2,847	<b>3,503</b>	3,448	<b>4,557</b>
<b>Total Liabilities</b>	<b>12,116</b>	<b>13,504</b>	<b>14,441</b>	<b>14,096</b>	<b>14,284</b>	<b>20,252</b>
<b>Equity</b>						
Capital Stock	10,884	10,884	10,891	<b>10,893</b>	10,894	<b>10,896</b>
Capital Surplus	6,224	6,224	6,231	<b>6,233</b>	6,235	<b>5,445</b>
Other Components of Equity	2,554	3,948	4,402	<b>3,147</b>	3,382	<b>4,279</b>
<b>Total Equity Attributable to Owners of the Parent</b>	<b>20,321</b>	<b>22,040</b>	<b>22,908</b>	<b>20,969</b>	<b>21,205</b>	<b>22,976</b>
Non-controlling Interests	151	278	892	<b>1,158</b>	1,419	<b>1,821</b>
<b>Total Equity</b>	<b>20,473</b>	<b>21,762</b>	<b>22,015</b>	<b>19,810</b>	<b>19,786</b>	<b>24,798</b>
<b>Total Equity and Liabilities</b>	<b>32,590</b>	<b>35,266</b>	<b>36,456</b>	<b>33,906</b>	<b>34,070</b>	<b>45,050</b>

## Consolidated Segment Information

### 【Pharmaceutical】

(Unit : Million yen)	FY2022				FY2023	
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD
Revenue	3,401	6,989	11,046	14,991	3,606	12,768
Segment profit	223	479	795	431	149	4,964
Segment Profit Margin	6.6%	6.9%	7.2%	2.9%	4.1%	38.9%


### 【Medical Device】

(Unit : Million yen)	FY2022				FY2023	
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD
Revenue	531	1,165	1,714	2,427	599	1,328
Segment profit	255	525	698	946	248	512
Segment Profit Margin	48.0%	45.1%	40.7%	39.0%	41.4%	38.6%

## Profitability-related Indicators

(Unit : Million yen)	FY2022				FY2023	
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD
Gross Profit Margin	86.0%	86.1%	85.0%	<b>84.6%</b>	86.4%	<b>90.5%</b>
OP before R&D Margin	24.1%	25.7%	26.0%	<b>22.5%</b>	24.5%	<b>47.7%</b>
Current Ratio	660.7%	677.4%	676.1%	<b>489.5%</b>	474.1%	<b>544.6%</b>
OP before R&D	946	2,093	3,313	<b>3,922</b>	1,032	<b>6,729</b>

## Operating Profit before R&D



	2017	2018	2019	2020	2021	2022
Revenue	2,648	5,018	7,446	11,803	12,690	17,418
Operating profit	154	568	1,302	1,220	1,624	1,377
R&D	268	530	758	1,243	2,015	2,545
<b>OP margin before R&amp;D</b>	<b>422</b>	<b>1,098</b>	<b>2,060</b>	<b>2,463</b>	<b>3,639</b>	<b>3,922</b>



## Stock Information

as of Jun 30, 2023

Total number of shares issued	47,487,843
Number of shares with full voting rights	47,470,800
Number of odd lot shares	15,643
Treasury Stock	1,400
Number of shareholders	16,340

as of Jun 30, 2023

Total number of authorized shares (common stock)	90,000,000
--	------------

### **【Major Shareholders】**

as of Jun 30, 2023

Name of shareholder	Number of shares held	Shareholding ratio
JP MORGAN CHASE BANK 380621	1,749,100	3.68%
Ying Luo	1,447,712	3.05%
SIX SIS LTD.	1,376,594	2.90%
MORGANSTANLEY SMITH BARNEY LLC CLIENTS FULLY PAID SEG ACCOUNT	1,000,000	2.11%
SBI Securities Co., Ltd.	386,424	0.81%
JP JPMSE LUX RE NOMURA INT PLC 1 EQ CO	373,611	0.79%
STATE STREET BANK WEST CLIENT - TREATY 505234	372,394	0.78%
Matsui Securities Co., Ltd.	370,600	0.78%
JP MORGAN CHASE BANK 385771	256,394	0.54%
Ueda Yagi Tanshi Co., Ltd.	247,400	0.52%
<b>Total</b>	<b>7,580,229</b>	<b>15.96%</b>

### **【Share Distribution by Owner】**

as of Jun 30, 2023

Owner Category	Number of Shareholders	Number of shares held	Shareholding ratio
Japanese financial institutions	7	5,323	1.12%
Financial instruments firms	34	18,896	3.98%
Other corporations	129	7,217	1.52%
Foreign corporations etc.	193	88,949	18.74%
Non Individuals	116	83,140	17.51%
Individuals	77	5,809	1.22%
Individuals and others	15,977	354,337	74.64%
<b>Total</b>	<b>16,340</b>	<b>474,722</b>	<b>100.00%</b>